RNAi Technology Market (2026 - 2033)

RNAi Technology Market Summary

The global RNAi technology market size was valued at USD 3.3 billion in 2025 and is projected to grow from USD 3.7 billion in 2026 to USD 9.5 billion by 2033, at a CAGR of 14.6% from 2026 to 2033. North America dominated the global market, accounting for the largest revenue share of 38.3% in 2025. The market growth can be attributed to the increasing prevalence of autoimmune diseases, rare disorders, and cancer across the globe.

Market Dynamics

The RNAi technology market is experiencing steady growth, driven by the increasing adoption of RNA interference in functional genomics, target validation, and drug discovery. Rising investments in genomics research, expanding therapeutic pipelines for rare and chronic diseases, and growing collaborations between pharmaceutical companies and research organizations are supporting market expansion. Moreover, the increasing focus on precision medicine, favorable funding for life science research, and the growing commercialization of RNAi-based therapeutics are expected to sustain market growth over the forecast period.

Market Concentration & Characteristics

The RNAi technology market is characterized by a high degree of innovation. Recent developments in molecular biology, biotechnology, and therapeutic development have propelled substantial innovation in the RNAi technology industry. Through the silencing of genes linked to diseases, RNA interference (RNAi) has been used more to create treatments for genetic disorders. Moreover, numerous RNAi-based therapies targeting a variety of illnesses, such as neurological disorders, metabolic diseases, and viral infections, are currently undergoing clinical trials at various stages.

The RNAi technology industry is witnessing a moderate to high level of mergers, acquisitions, and strategic partnerships as companies seek to strengthen RNAi pipelines, expand therapeutic capabilities, and accelerate the development of novel gene-silencing therapies. Industry participants are increasingly collaborating to leverage complementary expertise, delivery technologies, and commercialization capabilities. For instance, in December 2023, Innovent and SanegeneBio entered into a strategic partnership to develop an siRNA drug the treat hypertension. This trend is expected to support innovation, broaden product portfolios, and enhance the competitive landscape of the market.

The regulatory impact on the RNAi technology market is significant. Regulatory agencies such as the FDA and European Medicines Agency are developing and refining guidelines for advanced therapeutic applications. These guidelines aim to establish a framework for the assessment of clinical trials, addressing issues such as off-target effects, unintended consequences, and long-term safety.

The market has witnessed moderate product expansion, driven by increasing investments in RNAi therapeutics, expanding clinical pipelines, and growing commercialization of gene-silencing technologies. Companies are strengthening their product portfolios through new product launches, label expansions, and manufacturing advancements. For instance, in March 2025, Alnylam Pharmaceuticals received U.S. FDA approval for an expanded indication of AMVUTTRA (vutrisiran) for the treatment of ATTR amyloidosis with cardiomyopathy, significantly broadening its commercial RNAi therapeutics portfolio and patient reach. This is expected to strengthen the company's market position and accelerate the adoption of RNAi-based therapies.

The industry is witnessing a high level of regional expansion, driven by increasing genomics and molecular biology research, growing investments in RNA-based therapeutics, and expanding biotechnology infrastructure across emerging markets. Rising adoption of RNAi technologies in drug discovery and precision medicine is further strengthening the market presence across key geographic regions.

Analyst Perspective

The RNAi technology market is expected to witness significant growth, driven by increasing adoption of RNA interference in drug discovery, functional genomics, target validation, and therapeutic development. Rising investments in precision medicine, oncology research, and rare disease therapeutics are accelerating the demand for RNAi-based reagents, delivery technologies, and screening platforms. Continuous advancements in siRNA design, delivery systems, and high-throughput screening technologies are improving research efficiency and therapeutic potential. In addition, growing biopharmaceutical R&D activities and expanding clinical development of RNAi therapeutics are expected to support long-term market growth, encouraging companies to focus on innovation, strategic collaborations, and portfolio expansion.

Product & Service Insights

The products segment dominated the RNAi technology market, accounting for the largest revenue share of over 67.8% in 2025, due to the high specificity of RNAi-based tools in targeting and degrading mRNA, enabling precise molecular interventions. Rising investments are also strengthening product pipelines. For instance, in August 2023, ADARx Pharmaceuticals raised USD 200 million in Series C funding to advance its siRNA programs, including ADX-324 and ADX-038, and further develop its RNA-targeting and delivery platforms. Such investments are expected to support product innovation and segment growth over the forecast period.

The services segment is expected to grow at the fastest CAGR over the forecast period, driven by the increasing complexity of RNAi research and the growing demand for specialized expertise in drug discovery and therapeutic development. Contract Research Organizations (CROs) and specialized service providers offer end-to-end RNAi services, including target identification, assay development, preclinical studies, and clinical support, enabling biopharmaceutical companies to accelerate development timelines while reducing costs and operational complexity.

Application Insights

The drug discovery & development segment dominated the RNAi technology industry in 2025, accounting for a revenue share of 68.9%, and is expected to grow at the fastest CAGR during the forecast period. RNAi’s ability to precisely silence specific genes makes it an essential tool for studying gene function and validating therapeutic targets, supporting early-stage research. Rising investments, strategic collaborations for RNAi-based therapeutics, and continued advances in delivery technologies are further driving growth in this segment.

The functional genomics segment is expected to grow at a significant CAGR over the forecast period. driven by increasing research focused on understanding gene function and disease mechanisms. The growing use of functional genomics in target identification, biomarker discovery, and cancer research is accelerating the adoption of RNAi technologies, supporting the development of novel gene-based therapies.

End Use Insights

The pharmaceutical & biotechnology companies segment dominated the RNAi technology market, accounting for a revenue share of 56.5% in 2025. This is attributed to several factors, including ongoing research and development efforts, innovative therapies, and the introduction of advanced pharmaceutical products. In addition, the increasing demand for healthcare solutions and advancements in biotechnology contributed to the segment growth.

The CROs & CMOs segment is projected to grow at the fastest CAGR during the forecast period, as more pharmaceutical and biotech companies outsource to cut costs and boost efficiency. Businesses can access cutting-edge knowledge and technologies while concentrating on their core competencies by outsourcing research and manufacturing to specialized service providers.

Regional Insights

The North America RNAi technology market accounted for the largest global revenue share of 38.3% in 2025, driven by the strong presence of biotechnology and pharmaceutical companies, advanced research infrastructure, and increasing investments in RNA-based therapeutics. The growing development of RNAi therapies and innovations in oligonucleotide manufacturing further support regional growth. For instance, in November 2024, Codexis, Inc. successfully synthesized an oligonucleotide using an enzymatic manufacturing route, demonstrating advances in scalable manufacturing of RNA-based therapeutics.

U.S. RNAi Technology Market Trends

The U.S. RNAi technology industry is expected to grow significantly over the forecast period. The market growth can be attributed to the advancements in RNA-based technologies & their applications across various industries and the presence of key market players.

Europe RNAi Technology Market Trends

The Europe RNAi technology industry was identified as a lucrative region. With organizations like the Center for Genomic Regulation (CRG) and the National Center for Biotechnology (CNB) actively investigating RNA interference applications in healthcare, this further supports the regional market growth.

The UK RNAi technology market held a significant revenue share in 2025, driven by the rising prevalence of genetic disorders & diseases, the need for more efficient and effective treatments, and the growing interest in gene-editing technologies among researchers & scientists.

The RNAi technology market in Germany is anticipated to grow significantly over the forecast period. Germany’s strong R&D landscape in these areas is expected to improve the adoption of innovative therapies. Germany is one of the global leaders in scientific research, with renowned institutions & multiple biotechnology companies actively developing RNA-based research tools and novel therapeutics. For instance, in April 2024, Merck invested in a new Life Science Research Center in Germany, expanding capabilities in mRNA and bioproduction technologies to meet rising global demand in the market.

Asia Pacific RNAi Technology Market Trends

The Asia Pacific RNAi technology industry is expected to grow at the fastest CAGR of 16.6% during the forecast period, driven by the rising prevalence of genetic and chronic diseases, increasing investments in biotechnology and genomics research, and expanding biopharmaceutical manufacturing. High birth rates and the growing burden of inherited disorders in several countries are further supporting the adoption of RNAi-based therapeutics across the region.

The China RNAi technology market is growing significantly, driven by the rising prevalence of genetic and chronic diseases, the growing demand for personalized medicine, and expanding investments in RNA-based therapeutics. Government support for biotechnology innovation and the growing presence of domestic biopharmaceutical companies are further supporting market growth.

The RNAi technology market in Japan is witnessing rapid growth due to the growing adoption of precision medicine and personalized healthcare, which is boosting the demand for RNAi applications. In addition, Japan is a major player in scientific research, particularly in biotechnology & biopharmaceuticals.

MEA RNAi Technology Market Trends

The MEA RNAi technology industry is expected to grow exponentially over the forecast period. Cancer is a major public health concern in MEA. High mortality rates associated with the unavailability of resources, such as diagnostics, an underdeveloped healthcare infrastructure, and a lack of affordable treatment options, make MEA a preferred region for investment by large manufacturers. However, a limited number of institutes with advanced research facilities is limiting market growth in the region.

The Kuwait RNAi technology market is growing steadily, driven by increasing investments in precision medicine, expanding genomics research, and the gradual adoption of RNA-based therapeutics. Government initiatives to strengthen healthcare infrastructure and support biotechnology research are further contributing to the development of the country's RNAi ecosystem.

Key RNAi Technology Company Insights

Several well-known companies dominate the RNAi technology industry because of their extensive product lines, cutting-edge gene-silencing technologies, and consistent R&D expenditures. Due to their superior RNAi reagents, delivery systems, genome-wide siRNA/shRNA libraries, and robust global distribution networks, industry leaders such as Thermo Fisher Scientific, Inc.; Merck KGaA; Danaher; and Revvity hold significant market share. By providing integrated RNAi workflows that aid in drug discovery, functional genomics, and therapeutic development, companies continue to strengthen their position in the market.

Key RNAi Technology Companies

The following key companies have been profiled for this study on the RNAi technology market.

• Thermo Fisher Scientific, Inc.

• Merck KGaA

• Creative Biolabs

• GenScript

• Revvity

• Promega Corporation

• OriGene Technologies, Inc.

• Altogen Biosystems

• Danaher

• Bioneer Corporation

Competitive Benchmarking

Recent Developments

• In November 2025, SanegeneBio in China and the US signed a global licensing deal with Eli Lilly to develop LEAD-enabled RNAi therapies for metabolic diseases, reflecting rising global demand for advanced RNAi technologies.

• In October 2025, Creative Biolabs in the US launched a fully integrated RNA therapeutics platform, strengthening global RNAi research capacity and supporting rising demand for advanced RNAi-based drug discovery solutions.

• In May 2025, Biogen and City Therapeutics in the US formed a collaboration to develop RNAi therapies, reflecting rising global demand for next-generation RNAi technologies and advanced CNS-targeted delivery platforms.

• In August 2024, Skyhawk Therapeutics in the US entered a multibillion-dollar collaboration with Merck KGaA to discover small RNA-targeting molecules, reflecting surging global demand for RNA-modulation technologies in neurological drug development.

"We are proud to partner with Merck KGaA, Darmstadt, Germany a company with a strong heritage of innovation and a commitment to advancing transformative science."

- Bill Haney, Chief Executive Officer of Skyhawk Therapeutics.

RNAi Technology Market Report Scope

Global RNAi Technology Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global RNAi technology market report based on product & service, application, end use, and region:

• Product & Service Outlook (Revenue, USD Million/Billion, 2021 - 2033)

  • Products

    • siRNA products

    • miRNA products

    • Others

  • Services

• Application Outlook (Revenue, USD Million/Billion, 2021 - 2033)

  • Drug Discovery & Development

    • Neurology

    • Oncology

    • Infectious Diseases

    • Metabolic Diseases

    • Others

  • Functional Genomics

  • Others

• End Use Outlook (Revenue, USD Million/Billion, 2021 - 2033)

  • Pharmaceutical & Biotechnology Companies

  • Academic & Research Institutes

  • CROs & CMOs

• Regional Outlook (Revenue, USD Million/Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The RNAi technology market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each RNAi technologysegment quantified using the revenue-capture definitions in the table below.

Segment Definition

Delivered Customizations

This report has been delivered with the following In-depth customizations